Blum Robert I 4

What Happened

• Robert I. Blum, President & CEO and a director of Cytokinetics (CYTK), sold 7,500 shares in an open-market transaction on May 14, 2026. The shares were sold at $77.92 per share for a total proceeds of $584,400. This was a sale (S) — sales by executives are common and do not necessarily indicate a change in company outlook.

Key Details

• Transaction date: 2026-05-14
• Transaction type: Open-market sale (code S)
• Shares sold: 7,500 at $77.92 per share
• Total value: $584,400
• Shares owned after transaction: Not specified in the provided filing
• Footnotes: F1 and F2 note shares held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust (indicates some holdings are in family trusts)
• Filing date / Reported period: 2026-05-14 (Form 4 accession 0001061983-26-000052)
• No indication in the provided excerpt that this was part of a 10b5-1 plan or that the filing was late

Context

• For retail investors: purchases generally convey clearer bullish intent than routine sales. Executive sales can be for many personal reasons (taxes, diversification, trusts) and are not definitive signals about company fundamentals. Note the CEO remains an insider and trusts tied to family members hold shares per footnotes. Monitor future Form 4 filings for changes in ownership or patterned activity.